Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $210 price target on Amgen's (AMGN) shares following news that the company has won the Enbrel IP litigation with challenger Sandoz. The analyst notes that this challenge could have pulled forward Enbrel's LOE from 2029 to essentially right now, which has been the number 1 concern surrounding the stock. With shares up about 6% on this news, Raymond sees the reaction as appropriate and, while the stock is approaching his target at these levels, he believes shares are likely to grind higher on this removed overhang. Sandoz is a division of Novartis (NVS).